Trulicity Cost in District of Columbia: Prices, Insurance, and Savings for 2026

What Does Trulicity Actually Cost in DC Right Now?

The wholesale acquisition cost (WAC) set by Eli Lilly for Trulicity is $931 per month across all pen strengths, and that figure holds in District of Columbia retail pharmacies as the average cash-pay price in 2026. Patients without insurance or discount programs will pay close to that number at most DC pharmacies, though pricing can shift by $20 to $50 depending on the specific location.

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA for glycemic control in type 2 diabetes and for cardiovascular risk reduction in adults with established cardiovascular disease and T2D. The REWIND trial (N=9,901) demonstrated a 12% reduction in major adverse cardiovascular events (MACE) over a median 5.4-year follow-up with dulaglutide 1.5 mg weekly compared to placebo (Gerstein et al., Lancet 2019). That cardiovascular benefit is one reason prescribers and insurers in DC continue to authorize the drug despite its price tag.

Pharmacy pricing in the District tends to cluster tightly around the list price because DC lacks the competitive pharmacy density seen in larger states. Chain pharmacies like CVS and Walgreens on Connecticut Avenue, Capitol Hill, and Georgetown generally quote within 3% of the $931 WAC. Independent pharmacies may offer modest discounts, but rarely below $880 without a coupon or discount card.

DC Medicaid Coverage for Trulicity

District of Columbia Medicaid covers Trulicity, but patients need prior authorization before the pharmacy can fill the prescription. The PA process requires documentation that the patient has a confirmed type 2 diabetes diagnosis, has tried or has a contraindication to metformin, and has an A1C that warrants GLP-1 therapy.

DC Medicaid operates through managed care organizations (MCOs), primarily AmeriHealth Caritas DC and CareFirst Community Health Plan. Each MCO maintains its own preferred drug list (PDL), and Trulicity's formulary tier can differ between them. AmeriHealth Caritas DC typically places dulaglutide on a specialty tier requiring step therapy through metformin and at least one sulfonylurea or SGLT2 inhibitor before approval. CareFirst's PDL may require similar step therapy but has historically processed PA requests within 48 to 72 hours when the prescriber submits a completed DC Medicaid PA form.

The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease, and the REWIND trial's MACE data (Gerstein et al., 2019) supports that positioning. When the PA request cites cardiovascular indication, DC Medicaid MCOs approve at higher rates. Patients whose PA is denied can file an appeal through DC's Department of Health Care Finance (DHCF), which must respond within 30 days for standard requests or 72 hours for expedited reviews.

For DC residents enrolled in the DC Healthcare Alliance (the District's locally funded program for uninsured residents who do not qualify for Medicaid), Trulicity coverage is more limited. Alliance formularies tend to favor older, less expensive diabetes medications, and GLP-1 agonist coverage often requires an exception request with supporting clinical documentation.

How the Eli Lilly Savings Card Works in DC

Eli Lilly offers the Trulicity Savings Card, which can reduce out-of-pocket costs to as little as $25 per 30-day prescription for eligible commercially insured patients. The card is not valid for patients using government-funded insurance, including Medicaid, Medicare, TRICARE, or DC Healthcare Alliance.

To qualify, a patient must have commercial insurance that covers Trulicity (even partially), be a resident of the United States or Puerto Rico, and be 18 years or older. The savings card covers the difference between the patient's copay and $25, up to a maximum annual benefit that Eli Lilly adjusts periodically. As of early 2026, the cap sits at approximately $150 per fill in savings, which means patients with copays above $175 will still pay the difference.

Activation is straightforward. Patients can enroll online through Lilly's Trulicity website or by calling the number on the card. DC pharmacies process the card as a secondary insurance claim at the point of sale. The BIN, PCN, and group numbers on the card go into the pharmacy system after the primary insurance adjudicates. Processing typically adds 2 to 5 minutes at the counter.

One limitation DC patients should know: if the primary insurer requires a specialty pharmacy for Trulicity, the savings card must be processed through that specialty pharmacy. Some DC-area plans route GLP-1 agonists through CVS Specialty or Express Scripts, and in those cases, patients cannot use the card at a retail location.

Compounded Dulaglutide in District of Columbia

Compounded dulaglutide is available in DC through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy can prepare patient-specific dulaglutide formulations based on a valid prescription, provided the pharmacy holds proper DC Board of Pharmacy licensure.

The cost difference is significant. Brand Trulicity runs $931 per month. Compounded dulaglutide from a 503A pharmacy can cost substantially less depending on the pharmacy and dosage.

DC regulates compounding pharmacies through the DC Board of Pharmacy under the Department of Health. A 503A pharmacy operating in DC must be licensed in the District, maintain a valid prescription for each patient, and compound the medication in response to an individual prescription rather than in anticipation of demand (which would fall under 503B outsourcing facility rules). The FDA's guidance on compounding outlines the federal framework that overlays DC's local requirements.

Patients considering compounded dulaglutide should verify that the pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or holds equivalent state-level quality certifications. The prescribing clinician must write the prescription specifically for compounded dulaglutide, and patients should confirm the pharmacy uses pharmaceutical-grade dulaglutide active ingredient sourced from an FDA-registered supplier.

A practical note: compounded GLP-1 formulations may differ in pen device or delivery mechanism from brand Trulicity's prefilled single-dose pen. Patients switching from brand to compounded product should receive injection training from their pharmacy or provider to avoid dosing errors.

Insurance Plans That Cover Trulicity in DC

Beyond Medicaid, several major commercial insurers operating in the District cover Trulicity, each with its own formulary placement and cost-sharing structure.

CareFirst BlueCross BlueShield is the dominant commercial insurer in DC. Most CareFirst plans place Trulicity on a preferred brand or specialty tier. Copays for preferred brand tier typically range from $40 to $75 per fill. Specialty tier placement pushes the copay to $100 to $200, though the Eli Lilly savings card can offset a portion of that cost. CareFirst plans purchased through DC Health Link (the District's ACA marketplace) follow the same formulary but may have different cost-sharing based on the metal tier selected.

Aetna covers Trulicity on most DC-area plans but frequently requires step therapy through metformin. Copays range from $35 to $150 depending on the plan design. Aetna's specialty pharmacy, CVS Specialty, may handle dispensing for plans that classify Trulicity as a specialty medication.

UnitedHealthcare plans in DC vary widely. Employer-sponsored UHC plans often cover Trulicity with prior authorization. Individual market UHC plans may prefer semaglutide (Ozempic) over dulaglutide, requiring a formulary exception if the patient specifically needs Trulicity.

Kaiser Permanente Mid-Atlantic operates in the DC area and maintains a closed formulary. Kaiser providers can prescribe Trulicity, but the plan may prefer liraglutide (Victoza) or semaglutide depending on the current PDL cycle. Kaiser members fill prescriptions at Kaiser pharmacies, where copays are typically $30 to $50 for preferred brands.

For federal employees in DC (a large share of the District's insured population), the Federal Employees Health Benefits (FEHB) program covers Trulicity under most plans. The Blue Cross Blue Shield Federal Employee Program and GEHA are among the most commonly selected FEHB plans, and both include GLP-1 agonists on their formularies with varying PA requirements.

Telehealth Prescribing of Trulicity in DC

DC permits telehealth prescribing of Trulicity. The District's telehealth regulations, updated through emergency and permanent legislation during and after the COVID-19 public health emergency, allow licensed prescribers to initiate and manage GLP-1 therapy via audio-video visits without requiring an in-person encounter first.

A prescriber must hold an active DC medical license (or be authorized under an interstate compact agreement) to write a Trulicity prescription for a DC resident via telehealth. The DEA does not restrict GLP-1 agonists the way it does controlled substances, so no separate DEA registration is required for telehealth prescribing of dulaglutide.

Telehealth platforms that operate in DC and commonly prescribe GLP-1 agonists include HealthRX, which provides virtual consultations with board-certified physicians who can evaluate candidacy, write the prescription, and coordinate with DC pharmacies for fulfillment. Lab work (A1C, fasting glucose, renal function panel) can be ordered through local DC labs such as Quest Diagnostics or Labcorp, with results reviewed during a follow-up telehealth visit.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of type 2 diabetes supports the use of GLP-1 receptor agonists in patients with A1C above individualized targets despite metformin therapy, and telemedicine-based initiation of these agents has been validated in multiple health system analyses showing comparable glycemic outcomes to in-person starts.

Discount Programs and Assistance Options in DC

Several programs exist beyond the Lilly savings card for DC residents who need help affording Trulicity.

Lilly Cares Foundation is Eli Lilly's patient assistance program (PAP) for uninsured or underinsured patients. Eligibility generally requires household income at or below 400% of the federal poverty level and no prescription drug coverage. Approved patients receive Trulicity at no cost, shipped directly to their prescriber's office. Applications require prescriber involvement and income documentation.

RxAssist and NeedyMeds are databases that aggregate manufacturer and nonprofit assistance programs. DC residents can search both to find active dulaglutide programs and confirm current eligibility thresholds.

DC Health Link subsidies can indirectly reduce Trulicity costs by lowering monthly premiums and out-of-pocket maximums for DC residents who purchase ACA marketplace plans. A Silver plan with cost-sharing reductions can bring specialty drug copays down to $50 to $75 for patients between 150% and 250% of FPL.

340B program pharmacies in DC (affiliated with Federally Qualified Health Centers such as Unity Health Care and Community of Hope) may dispense Trulicity at reduced cost to eligible patients. The Health Resources and Services Administration (HRSA) oversees the 340B program, which requires drug manufacturers to provide outpatient drugs at significantly discounted prices to eligible healthcare organizations serving low-income populations.

Trulicity Dosing and What to Expect on Therapy

Dulaglutide is injected once weekly, on the same day each week, at any time of day, with or without food. The starting dose is 0.75 mg weekly, which can be increased to 1.5 mg after 4 weeks if additional glycemic control is needed. The prescribing information allows further titration to 3.0 mg and then 4.5 mg in 4-week increments for patients who need more aggressive A1C reduction.

In the AWARD-11 trial, dulaglutide 4.5 mg reduced A1C by 1.87% from baseline at 36 weeks compared to 1.54% with 1.5 mg (Frias et al., Lancet 2021). The most common side effects are gastrointestinal: nausea (affecting approximately 12% to 21% of patients depending on dose), diarrhea (8% to 12%), and vomiting (6% to 12%). These effects typically peak during the first 2 to 4 weeks and diminish as the body adjusts.

Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado, has stated: "GLP-1 receptor agonists like dulaglutide represent a class of medications that address both glycemic control and cardiovascular risk, which is exactly what we need for the type 2 diabetes population carrying the highest burden of heart disease."

The ADA's Standards of Care 2024 recommend GLP-1 receptor agonists with proven cardiovascular benefit (dulaglutide, liraglutide, semaglutide) for patients with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Dulaglutide's REWIND trial demonstrated this benefit with a hazard ratio of 0.88 (95% CI 0.79 to 0.99) for the primary composite MACE endpoint (Gerstein et al., Lancet 2019).

Comparing Trulicity to Other GLP-1 Options in DC

DC patients and prescribers sometimes weigh Trulicity against other GLP-1 receptor agonists. Semaglutide (Ozempic) has a list price of approximately $935 per month and produced greater A1C reduction and weight loss in the head-to-head SUSTAIN 7 trial: semaglutide 1.0 mg reduced A1C by 1.8% vs. dulaglutide 1.5 mg at 1.4% over 40 weeks (Pratley et al., Lancet Diabetes Endocrinol 2018). Tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, lists at roughly $1,023 per month and showed A1C reductions of up to 2.58% in the SURPASS program (Rosenstock et al., NEJM 2021).

The choice often comes down to formulary positioning. CareFirst DC plans have historically favored Trulicity or Ozempic depending on the plan year's negotiations. Kaiser Mid-Atlantic may rotate preference among the three. Patients stable on dulaglutide who switch insurers should confirm formulary status before the plan year begins to avoid coverage gaps.

For DC patients whose primary goal is weight loss rather than diabetes management, dulaglutide is FDA-approved only for type 2 diabetes and cardiovascular risk reduction. It is not approved for weight management, unlike semaglutide 2.4 mg (Wegovy). Prescribers who write off-label dulaglutide for weight loss may face insurance denials in DC.

Patients filling Trulicity at a DC pharmacy should store the prefilled pen in the refrigerator at 36°F to 46°F (2°C to 8°C) until use, though a single pen can remain at room temperature (up to 86°F / 30°C) for up to 14 days before injection.